These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33780197)

  • 41. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
    de Oliveira Almeida VC; Ribeiro DD; Gomes KB; Godard AL
    Mol Diagn Ther; 2014 Dec; 18(6):675-83. PubMed ID: 25312789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.
    Jiang NX; Ge JW; Xian YQ; Huang SY; Li YS
    Biomed Rep; 2016 Apr; 4(4):453-458. PubMed ID: 27073631
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation.
    Huang TS; Zhang L; He Q; Li YB; Dai ZL; Zheng JR; Cheng PQ; He YS
    Australas Phys Eng Sci Med; 2017 Mar; 40(1):249-258. PubMed ID: 28083852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.
    Farajzadeh-Dehkordi M; Samiee-Rad F; Farzam SS; Javadi A; Cheraghi S; Hamedi-Asl D; Rahmani B
    Pharmacol Rep; 2023 Jun; 75(3):695-704. PubMed ID: 37039974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
    Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
    Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.
    Cini M; Legnani C; Cosmi B; Guazzaloca G; Valdrè L; Frascaro M; Palareti G
    Eur J Clin Pharmacol; 2012 Aug; 68(8):1167-74. PubMed ID: 22349464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.
    Ndadza A; Muyambo S; Mntla P; Wonkam A; Chimusa E; Kengne AP; Ntsekhe M; Dandara C
    J Thromb Haemost; 2021 Dec; 19(12):2957-2973. PubMed ID: 34382722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.
    Zambon CF; Pengo V; Padrini R; Basso D; Schiavon S; Fogar P; Nisi A; Frigo AC; Moz S; Pelloso M; Plebani M
    Pharmacogenomics; 2011 Jan; 12(1):15-25. PubMed ID: 21174619
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of
    Al-Eitan LN; Almasri AY; Khasawneh RH
    Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30486437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.
    You JH; Wong RS; Waye MM; Mu Y; Lim CK; Choi KC; Cheng G
    J Thromb Thrombolysis; 2011 Jan; 31(1):113-8. PubMed ID: 20585834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of
    Holail J; Mobarak R; Al-Ghamdi B; Aljada A; Fakhoury H
    Drug Metab Pers Ther; 2022 Apr; ():. PubMed ID: 35365981
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.
    Kudzi W; Ahorhorlu SY; Dzudzor B; Olayemi E; Nartey ET; Asmah RH
    BMC Res Notes; 2016 Dec; 9(1):507. PubMed ID: 27938396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.